Two Sigma Advisers LP Has $34.51 Million Stake in Genmab A/S (NASDAQ:GMAB)

Two Sigma Advisers LP lifted its stake in Genmab A/S (NASDAQ:GMAB - Free Report) by 168.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,653,500 shares of the company's stock after buying an additional 1,038,400 shares during the period. Two Sigma Advisers LP owned about 0.25% of Genmab A/S worth $34,509,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. Raymond James Financial Inc. acquired a new position in Genmab A/S in the 4th quarter valued at approximately $2,463,000. AIMZ Investment Advisors LLC bought a new position in Genmab A/S in the fourth quarter worth $3,525,000. Mirae Asset Global Investments Co. Ltd. boosted its stake in Genmab A/S by 229.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 49,727 shares of the company's stock worth $1,033,000 after buying an additional 34,652 shares in the last quarter. Blue Trust Inc. increased its holdings in Genmab A/S by 33.4% in the 4th quarter. Blue Trust Inc. now owns 5,757 shares of the company's stock valued at $120,000 after buying an additional 1,442 shares during the period. Finally, Sei Investments Co. increased its holdings in Genmab A/S by 55.2% in the 4th quarter. Sei Investments Co. now owns 57,702 shares of the company's stock valued at $1,205,000 after buying an additional 20,525 shares during the period. 7.07% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GMAB has been the subject of a number of analyst reports. Truist Financial reduced their price objective on shares of Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a report on Tuesday, March 11th. Leerink Partners raised shares of Genmab A/S from a "market perform" rating to an "outperform" rating and set a $27.00 price target for the company in a report on Thursday, February 13th. Sanford C. Bernstein lowered shares of Genmab A/S from a "market perform" rating to an "underperform" rating in a research report on Tuesday, April 1st. HC Wainwright reaffirmed a "buy" rating and set a $37.00 price objective (down previously from $50.00) on shares of Genmab A/S in a report on Wednesday, April 9th. Finally, BNP Paribas upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Tuesday, February 11th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $39.17.

Genmab A/S Stock Performance

GMAB traded down $0.22 during midday trading on Monday, hitting $20.81. The company had a trading volume of 1,247,688 shares, compared to its average volume of 1,131,782. The company has a market capitalization of $13.34 billion, a PE ratio of 11.96, a P/E/G ratio of 2.65 and a beta of 1.04. Genmab A/S has a twelve month low of $17.24 and a twelve month high of $28.96. The firm's 50-day simple moving average is $19.77 and its 200-day simple moving average is $20.67.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported $0.31 EPS for the quarter, beating the consensus estimate of $0.23 by $0.08. The business had revenue of $715.00 million for the quarter, compared to analysts' expectations of $5.17 billion. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, sell-side analysts anticipate that Genmab A/S will post 1.45 EPS for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.